Literature DB >> 12145420

Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery.

U Plöckinger1, B Wiedenmann.   

Abstract

Surgery is the only curative approach in neuroendocrine gastro-entero-pancreatic (GEP) tumors. As cure is highly dependent of tumor size, early diagnosis is a prerequisite for surgical success. Diagnosis of nonfunctioning tumors of the pancreas or midgut origin is due to symptoms related to the tumor burden, thus early diagnosis is mostly incidental. Functioning pancreatic tumors should be operated early in the course of the disease to provide cure. No genetic screening is available for sporadic GEP tumors. In patients with MEN-1 syndrome genetic screening is recommended to restrict the burden of clinical screening to those with positive test results. Due to the nature of the disease cure may not be achieved, however prevention of cancer may be obtained for one or two decades of life, especially in patients with gastrinoma or nonfunctioning tumors. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12145420     DOI: 10.1159/000063164

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  12 in total

1.  Use of Endoscopy in the Diagnosis of a Patient With an ACTH-producing Pancreatic Tumor.

Authors:  Corlan O Adebajo; Charles Dye; John Liang; Matthew T Moyer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

2.  Tumor Lysis Syndrome in an Unusual Metastatic Pancreatic Neuroendocrine Tumor with Ectopic ACTH Secretion.

Authors:  Michael Shusterman; Noah A Bloomgarden; Susan T Sotardi; Aditi Shastri
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 3.  Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Masayuki Imamura; Izumi Komoto; Shuichi Ota
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

4.  Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.

Authors:  Francesco Giudici; Tiziana Cavalli; Francesca Giusti; Giorgio Gronchi; Giacomo Batignani; Francesco Tonelli; Maria Luisa Brandi
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

5.  Clinical profile of insulinoma: analysis from a tertiary care referral center in India.

Authors:  Raju A Gopal; Shrikrishna V Acharya; Sunil K Menon; Tushar R Bandgar; Padma S Menon; Nalini S Shah
Journal:  Indian J Gastroenterol       Date:  2010-10-16

6.  Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors.

Authors:  Kristin Heeger; Massimo Falconi; Stefano Partelli; Jens Waldmann; Stefano Crippa; Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2014-02-14       Impact factor: 3.445

7.  Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Authors:  S Chiloiro; F Lanza; A Bianchi; G Schinzari; M G Brizi; A Giampietro; V Rufini; F Inzani; A Giordano; G Rindi; A Pontecorvi; L De Marinis
Journal:  Endocrine       Date:  2017-05-31       Impact factor: 3.633

Review 8.  Surgical treatment of sporadic gastrinoma.

Authors:  Kerstin Lorenz; Henning Dralle
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Middle pancreatectomy: indications, short- and long-term operative outcomes.

Authors:  Stefano Crippa; Claudio Bassi; Andrew L Warshaw; Massimo Falconi; Stefano Partelli; Sarah P Thayer; Paolo Pederzoli; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

10.  Management of insulinomas: analysis from a tertiary care referral center in India.

Authors:  Thomas V Paul; Jubbin J Jacob; Senthil K Vasan; Nihal Thomas; Simon Rajarathnam; Ben Selvan; M J Paul; Deepak Abraham; Aravindan Nair; M S Seshadri
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.